Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities

There are no FDA-approved drugs to mitigate the delayed effects of radiation exposure that may occur after a radiological attack or nuclear accident. To date, angiotensin-converting enzyme inhibitors are one of the most successful candidates for mitigation of hematopoietic, lung, kidney, and brain i...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Pharmacol
Egile Nagusiak: Medhora, Meetha, Phadnis, Preeya, Narayanan, Jayashree, Gasperetti, Tracy, Zielonka, Jacek, Moulder, John E., Fish, Brian L., Szabo, Aniko
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2021
Gaiak:
Pharmacology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8111401/
https://ncbi.nlm.nih.gov/pubmed/33986677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.646076
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak